Artificial intelligence is fundamentally changing every aspect of drug development, significantly shortening the traditional 10-15 year drug development cycle. From target discovery to lead compound optimization, from clinical trial prediction to drug repositioning, AI big models are becoming the core driving force in the pharmaceutical industry.
Traditional drug development heavily relies on experience trial and error and extensive experimental screening, with an average cost of over 2.6 billion US dollars per new drug development. AI technology has significantly reduced this cost through computational simulations. Taking target discovery as an example, AlphaFold and its subsequent iterative models can directly predict three-dimensional structures from protein sequences, solving the problem of relying on time-consuming methods such as X-ray crystallography to obtain protein structure information in the past.
In the field of molecular generation, molecular design models based on generative AI can generate candidate molecules with ideal pharmacological properties from scratch. These models can design completely new lead compounds by learning the chemical spatial distribution of millions of known molecules. In 2026, multiple biotechnology companies have entered clinical trials using AI designed molecules, covering multiple therapeutic fields such as tumors, autoimmune diseases, and rare diseases.
AI also shows great potential in optimizing clinical trials. By analyzing massive patient data, AI models can predict the efficacy and safety of drugs in different populations, optimize subject screening schemes, and improve the success rate of clinical trials. Preclinical toxicity prediction is also an important application direction of AI. Large models can predict key indicators such as liver toxicity and cardiac toxicity of candidate molecules, reducing the loss of later failures.
Drug repositioning is another efficient application scenario for AI. By analyzing the relationship between the molecular structure of existing drugs and their biological effects, AI can quickly identify the therapeutic potential of known drugs for new indications. This method significantly reduces security risks and shortens the development cycle.
With the development of multimodal big models, future AI pharmaceuticals will integrate multi-level data such as genomics, proteomics, metabolomics, etc., to construct a more comprehensive view of drug development. This will drive precision medicine from concept to clinical practice.